Skip to main content

Table 1 Demographics1

From: Serum Müllerian inhibiting substance levels are lower in premenopausal women with breast precancer and cancer

 

Benign

Precancer

Cancer

Mean ± SD

Sample size

8

8

14

Time from sample collection to analysis (years)

3.02 ± 1.04

4.19 ± 2.40

2.24 ± 0.49

Participant age

42.4 ± 3.3

45.5 ± 4.5

43.7 ± 4.4

Age at menarche

13.1 ± 1.2

12.6 ± 1.0

12.6 ± 1.6

BMI

30.7 ± 6.9

30.7 ± 10.0

27.4 ± 9.1

MIS (ng/mL)

1.07 ± 0.90

0.30 ± 0.50

0.58 ± 0.80

ln(MIS (ng/mL)

-0.27 ± 0.93

-2.91 ± 2.24

-2.31 ± 2.55

Frequency (%)

1st degree relative with breast cancer

1 (12.5%)

3 (37.5%)

2 (14.3%)

Current OCP use

1 (12.5%)

0 (0%)

2 (14.3%)

History of OCP use

4 (50%)

6 (75%)

12 (85.7%)

  1. 1: Results for time to sample collection, participant age, age at menarche, body mass index (BMI), and mullerian inhibiting substance (MIS) are mean +/- standard deviation. Results for 1st degree relative with breast cancer, current and history of oral contraceptive pill (OCP) use are frequency (%).